P-266 Aflibercept as a second line chemotherapy in metastatic colorectal cancer. One centre experience

González-Astorga, Beatriz; González-Flores, E.; Urena, M.T. Delgado; García-García, Juan; Conde, V.; Sanchez-Toro, C.; Villaescusa, A Puebla

doi:10.1093/annonc/mdv233.263

Annals of Oncology

2015

DOI: 10.1093/annonc/mdv233.263

|View full text |Cite

P-266 Aflibercept as a second line chemotherapy in metastatic colorectal cancer. One centre experience

Beatriz González-Astorga

E. González-Flores

M.T. Delgado Urena

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Aflibercept

2016

Reactions Weekly

View full text Add to dashboard Cite

Aflibercept Hypertension and diarrhea: 2 case reportsIn a study of 20-patients, two patients [ages and sexes not stated] were found to have developed diarrhoea or hypertension during treatment with aflibercept for metastatic colorectal cancer (mCRC).The patients with mCRC were treated with aflibercept [dosages and routes not stated] as a second line treatment. The aflibercept treatment was discontinued due to toxicity in 2 patients. One patient developed hypertension, while another developed diarrhoea [durations of treatments to reaction onsets and outcomes not stated].Author comment: "[W]e treated 20 patients with FOLFIRI plus aflibercept each every 15 days as a second line chemotherapy treatment for mCRC". "Observed side effects were consistent to previous III phase trial, and the main causes of aflibercept discontinuation therapy were hypertension and diarrhea." Gonzalez-Astorga B, et al. Aflibercept as a second line chemotherapy in metastatic colorectal cancer. One centre experience. Annals of Oncology 26 (Suppl. 4): iv78 abstr. P-266, Jun 2015. Available from: URL: http://doi.org/10.1093/annonc/ mdv233.263 [abstract] -Spain

show abstract

Aflibercept

2016

Reactions Weekly

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P-266 Aflibercept as a second line chemotherapy in metastatic colorectal cancer. One centre experience

Cited by 1 publication

References 0 publications

Aflibercept

Aflibercept

Contact Info

Product

Resources

About